Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

Markers released top-line results today after previously reporting the trial succeeded.

This news item is fetched from a public RSS feed. Title, summary, and image are © their respective publisher; follow the link above to read the full article on the original site.